Agile fintech players are digitalising the payments industry, leaving traditional banks in the dust

The Internet of Things is set to bring a seismic shift to the way we use technology. But first, cities must work out how to power the new masses of internet-dependent devices

Samsung’s success in the wake of a series of scandals shows that the smartphone maker truly could be too big to fail

Chinese e-commerce giant Alibaba said it expects to spend $15bn on R&D over the next three years

The European Commission ordered Ireland to recover the US tech giant’s unpaid taxes in August 2016 after deeming the country’s benefits to be illegal

Toshiba has officially committed to selling its prized memory chip unit to Pangea, a Bain Capital-led consortium

Equifax has been hit by a data breach which affected 143 million customers, and could prompt an SEC investigation after executives sold $2m of shares before the attack went public

With rapid advancements in technology linked to polarised job markets and a steady rise in inequality, Kim Darrah asks: is technology turning against us?

With the advent of online shopping and the ubiquity of smartphones, purchases have fast become digital. Now, social media is shaping the future of retail

The Intercontinental Exchange has partnered with a timekeeping laboratory ahead of new regulatory requirements regarding time traceability

By making tweaks to its search engine algorithms, Google hopes to demote misleading information, offensive articles and unsupported conspiracy theories from search results

As one of Silicon Valley’s most innovative entrepreneurs, Elon Musk has forged a remarkable career from thinking outside of the box

European Commission approves $130bn merger between Dow Chemicals and DuPont on condition of certain divestments

The rapid development of artificial intelligence and robotics has prompted fears among leaders at Davos, with the World Economic Forum warning of the technologies’ detrimental long-term effects

A new OECD report has criticised the pricing strategy of the pharmaceutical industry, claiming many new drugs are simply bad value for money